111 related articles for article (PubMed ID: 3476335)
1. ["Immunosuppressive acidic protein" (IAP)--an improvement for tumor marker diagnosis in epithelial ovarian cancer?].
Sevelda P; Haider F; Spona J
Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):452-5. PubMed ID: 3476335
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
3. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
4. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
Crombach G; Zippel HH; Würz H
Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125].
Sevelda P; Wagner G
Wien Klin Wochenschr; 1987 Nov; 99(21):768-70. PubMed ID: 3480655
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
7. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
8. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
Paulick R; Kaesemann H; Caffier H
Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers in gynecologic diseases].
Geyer H; Kleine W
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
[TBL] [Abstract][Full Text] [Related]
10. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract][Full Text] [Related]
11. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
12. [Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y; Kurachi K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Apr; 38(4):554-60. PubMed ID: 3701144
[TBL] [Abstract][Full Text] [Related]
13. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
Sevelda P; Salzer H; Dittrich C; Spona J
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
16. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
17. [Studies on immunosuppressive acidic protein (IAP) in ovarian tumors].
Miyoshi T; Nishimura H; Hamai J; Yamada T; Tomoo Y; Kobayashi H; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):923-9. PubMed ID: 2991397
[TBL] [Abstract][Full Text] [Related]
18. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
Miladinović D; Paunović R; Paunković N
Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
[TBL] [Abstract][Full Text] [Related]
19. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
20. Analysis of CA-125 levels in the sera of patients with non-ovarian carcinomas and non-malignant diseases.
Marechal F; Berthiot G; Kritly T; Legrand MG; Deltour G; Cattan A
Anticancer Res; 1989; 9(3):593-8. PubMed ID: 2764505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
